310 related articles for article (PubMed ID: 16473346)
1. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
Groneberg DA; Rabe KF; Fischer A
Eur J Pharmacol; 2006 Mar; 533(1-3):182-94. PubMed ID: 16473346
[TBL] [Abstract][Full Text] [Related]
2. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
Onoue S; Yamada S; Yajima T
Peptides; 2007 Sep; 28(9):1640-50. PubMed ID: 17537541
[TBL] [Abstract][Full Text] [Related]
3. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
4. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
6. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
[TBL] [Abstract][Full Text] [Related]
7. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal polypeptide as mediator of asthma.
Groneberg DA; Springer J; Fischer A
Pulm Pharmacol Ther; 2001; 14(5):391-401. PubMed ID: 11603952
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
10. [Vasoactive intestinal polypeptide in the respiratory tract: physiology and pathophysiology].
Groneberg DA; Rabe KF; Wagner U; Fischer A
Pneumologie; 2004 May; 58(5):330-8. PubMed ID: 15162259
[TBL] [Abstract][Full Text] [Related]
11. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
15. Temporal and spatial distribution of VIP, CGRP and their receptors in the development of airway hyperresponsiveness in the lungs.
Ren YH; Qin XQ; Guan CX; Luo ZQ; Zhang CQ; Sun XH
Sheng Li Xue Bao; 2004 Apr; 56(2):137-46. PubMed ID: 15127121
[TBL] [Abstract][Full Text] [Related]
16. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal polypeptide (VIP) in lung function and disease.
Said SI
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Dec; 29(12):1525-31. PubMed ID: 1687288
[No Abstract] [Full Text] [Related]
18. Helospectin I and II evoke vasodilation in the intact peripheral microcirculation.
Tsueshita T; Onyükusel H; Sethi V; Gandhi S; Rubinstein I
Peptides; 2004 Jan; 25(1):65-9. PubMed ID: 15003357
[TBL] [Abstract][Full Text] [Related]
19. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide as a healing mediator in Crohn's disease.
Arranz A; Abad C; Juarranz Y; Leceta J; Martinez C; Gomariz RP
Neuroimmunomodulation; 2008; 15(1):46-53. PubMed ID: 18667799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]